Effectiveness of oral iron to manage anemia in long-term hemodialysis patients with the use of ultrapure dialysate

Experimental and Therapeutic Medicine

Volumn 1, Issue 5, 2010, Pages 777-781

  Tsuchida, Akiyasu ^a   Paudyal, Bishnuhari ^b   Paudyal, Pramila ^c   Ishii, Yoshitaka ^a   Hiromura, Keiju ^a   Nojima, Yoshihisa ^a   Komai, Minoru ^a  

^a Sanshi Group Hikari Clinic   (Japan)

^b Departments of Diagnostic Radiology and Nuclear Medicine   (Japan)

^c GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Anemia; Hemodialysis; Intravenous iron; Oral iron; Ultrapure dialysate

Indexed keywords

BETA 2 MICROGLOBULIN; CIDEFERRON; CREATININE; FERRITIN; FERROUS FUMARATE; HEMOGLOBIN; IRON; RECOMBINANT ERYTHROPOIETIN; SODIUM CHLORIDE; TRANSFERRIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ARTICLE; CHRONIC GLOMERULONEPHRITIS; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DIALYSATE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG INFUSION; DRY WEIGHT; FEMALE; FERRITIN BLOOD LEVEL; GASTROINTESTINAL DISEASE; HEMATOCRIT; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON BLOOD LEVEL; IRON THERAPY; KIDNEY DISEASE; KIDNEY SCLEROSIS; MALE; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TABLET; TRANSFERRIN BLOOD LEVEL; TREATMENT OUTCOME;

EID: 77955217185     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2010.122     Document Type: Article

References (25)

1. Van Wyck D, Eckardt KU, Uhlig K, Rocco M and Levin A: Appraisal of evidence and control of bias in the kidney disease outcomes quality initiative guideline development process. Clin JAm Soc Nephrol 2: 8-10, 2007.
2. Fishbane S, Kalantar-Zadeh K and Nissenson AR: Serum ferritin in chronic kidney disease: reconsidering the upper limit for iron treatment. Semin Dial 17: 336-341, 2004.
3. Kalantar-Zadeh K, McAllister CJ, Lehn RS, Lee GH, NissensonAR and Kopple JD: Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. Am JKidney Dis 42: 761-773, 2003.
4. Fishbane S and Maesaka JK: Iron management in end-stage renal disease. Am JKidney Dis 29: 319-333, 1997.
5. Wingard RL, Parker RA, Ismail N and Hakim RM: Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin. Am JKidney Dis 25: 433-439, 1995.
6. Kapoian T, O'Mara NB, Singh AK, et al: Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. JAm Soc Nephrol 19: 372-379, 2008.
7. Macdougall IC: Intravenous administration of iron in epoetin-treated haemodialysis patients - which drugs, which regimen? Nephrol Dial Transplant 15: 1743-1745, 2000.
8. Coyne DW, Kapoian T, Suki W, et al: Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. JAm Soc Nephrol 18: 975-984, 2007.
9. Rozen-Zvi B, Gafter-Gvili A, Paul M, Leibovici L, Shpilberg O and Gafter U: Intravenous versus oral iron supplementation for the treatment of anemia in CRF: systematic review and meta-analysis. Am JKidney Dis 52: 897-906, 2008.
10. Lenga I, Lok C, Marticorena R, Hunter J, Dacouris N and Goldstein M: Role of oral iron in the management of long-term hemodialysis patients. Clin JAm Soc Nephrol 2: 688-693, 2007.
11. Stoves J, Inglis H and Newstead CG: A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. Nephrol Dial Transplant 16: 967-974, 2001.
12. Charytan C, Qunibi W and Bailie GR: Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron Clin Pract 100: 55-62, 2005.
13. Muñoz M, Villar I and García-Erce JA: An update on iron physiology. World JGastroenterol 15: 4617-4626, 2009.
14. Pérez-García R, Martín-Malo A, Fort J, et al: Baseline characteristics of an incident haemodialysis population in Spain: results from ANSWER- a multicentre, prospective, observational cohort study. Nephrol Dial Transplant 24: 578-588, 2009.
15. Malyszko J and Mysliwiec M: Hepcidin in anemia and inflammation in chronic kidney disease. Kidney Blood Press Res 30: 15-30, 2007.
16. Nakai S, Masakane I, Shigematsu T, et al: An overview of regular dialysis treatment in Japan (as of 31 December 2007). Ther Apher Dial 13: 457-504, 2009.
17. Agarwal R, Rizkala AR, Bastani B, Kaskas MO, Leehey DJ and Besarab A: A randomized controlled trial of oral versus intravenous iron in chronic kidney disease. Am J Nephrol 26: 445-454, 2006.
18. Boddy K, Lawson DH, Linton AL and Will G: Iron metabolism in patients with chronic renal failure. Clin Sci 39: 115-121, 1970.
19. Hezode C, Cazeneuve C, Coue O, et al: Liver iron accumulation in patients with chronic active hepatitis C: prevalence and role of hemochromatosis gene mutations and relationship with hepatic histological lesions. JHepatol 31: 979-984, 1999.
20. Lim PS, Wei YH, Yu YL and Kho B: Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy. Nephrol Dial Transplant 14: 2680-2687, 1999.
21. Nascimento MM, Suliman ME, Bruchfeld A, et al: The influence of hepatitis Cand iron replacement therapy on plasma pentosidine levels in haemodialysis patients. Nephrol Dial Transplant 19: 3112-3116, 2004.
22. Feldman HI, Santanna J, Guo W, et al: Iron administration and clinical outcomes in hemodialysis patients. JAm Soc Nephrol 13: 734-744, 2002.
23. Williams P and Griffiths E: Bacterial transferrin receptors - structure, function and contribution to virulence. Med Microbiol Immunol 181: 301-322, 1992.
24. Patruta SI, Edlinger R, Sunder-Plassmann G and Hörl WH: Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency. J Am Soc Nephrol 9: 655-663, 1998.
25. Lonnemann G, Krautzig S and Koch KM: Quality of water and dialysate in haemodialysis. Nephrol Dial Transplant 11: 946-949, 1996.